Month: September 2026

Strong commercial execution and AI momentum drive organic ASV growth of 7.0%

NORWALK, Conn., Sept. 30, 2026 (GLOBE NEWSWIRE) — FactSet (NYSE: FDS) (NASDAQ: FDS), a leading global intelligence and AI solutions provider to the financial markets, today announced results for its fourth quarter and fiscal 2026 ended August 31, 2026.

Q4 and Fiscal 2026 Highlights Robust growth: Q4 GAAP revenues grew 6.3% year over year to $634.7 million, with organic revenues up 7.1%. Organic ASV increased by $168.2 million year over year to $2,568.2 million, up 7.0%. Commercial excellence: Enterprise relationships deepened. Annual ASV retention remained above 95%. During Q4, average renewal contract length increased by ~30%. AI momentum: AI solutions ASV added in fiscal 2026 more than doubled year over year. Capital returns: FactSet returned more than $179 million to shareholders in Q4, including $138 million in share repurchases and more than $41 million in dividends. During fiscal 2026, FactSet returned $808 million to shareholders and achieved its twenty-seventh consecutive year of dividend increases.

“FactSet delivered strong results, highlighted by a record increase in organic ASV for both the fourth quarter and fiscal year with continued momentum across our AI and data solutions. During the year, we accelerated innovation, strengthened commercial execution, and improved productivity across the organization.

“As demand for trusted financial intelligence continues to grow, FactSet’s high-quality data, embedded workflows, service excellence, and deep client relationships position us to drive sustainable growth and long-term shareholder value.”

– Sanoke Viswanathan, CEO

Key Financial Measures*

(Condensed and Unaudited)	Three Months Ended								Twelve Months Ended							Latest
	August 31,								August 31,							FY2026
(Results in thousands, except per share data)		2026			2025		Change			2026			2025		Change	Guidance
Revenues	$	634,698		$	596,901		6.3 %		$	2,476,256		$	2,321,748		6.7 %	$2,450 – $2,470M
Organic revenues	$	635,543		$	593,503		7.1 %		$	2,464,614		$	2,309,287		6.7 %
Operating income	$	156,624		$	177,321		(11.7)%		$	699,957		$	748,303		(6.5)%
Adjusted operating income	$	209,393		$	201,701		3.8 %		$	855,308		$	843,432		1.4 %
Operating margin		24.7	%		29.7	%				28.3	%		32.2	%		29.5% – 31.0%
Adjusted operating margin		33.0	%		33.8	%				34.5	%		36.3	%		34.0% – 35.5%
Net income	$	121,127		$	153,616		(21.1)%		$	533,481		$	597,040		(10.6)%
Adjusted net income	$	160,887		$	154,590		4.1 %		$	659,498		$	651,617		1.2 %
Adjusted EBITDA	$	209,212		$	244,555		(14.5)%		$	911,407		$	934,973		(2.5)%
Diluted EPS	$	3.41		$	4.03		(15.4)%		$	14.57		$	15.55		(6.3)%	$14.85 – $15.35
Adjusted diluted EPS	$	4.52		$	4.05		11.6 %		$	18.01		$	16.98		6.1 %	$17.25 – $17.75

* See reconciliation of U.S. GAAP to adjusted key financial measures in the back of this press release.

Fourth Quarter Fiscal 2026 Highlights

• GAAP revenues increased 6.3% or $37.8 million to $634.7 million compared with $596.9 million in the prior year period.
• Organic revenues grew 7.1% year over year to $635.5 million.
• Annual Subscription Value (“ASV”) was $2,565.2 million at August 31, 2026.
• Organic ASV was $2,568.2 million at August 31, 2026, up 7.0% or $168.2 million year over year.
• GAAP operating margin was 24.7% compared with 29.7% in the prior year period, primarily due to higher employee compensation costs, mainly driven by one-time restructuring charges and ASV-linked incentive plans, partially offset by an increase in revenues.
• Adjusted operating margin, which excludes acquisition-related intangible asset amortization and non-recurring items, was 33.0% compared with 33.8% in the prior year period, mainly due to higher compensation expense from ASV-linked incentive plans and technology-related expenses.
• GAAP diluted EPS was $3.41 compared with $4.03 for the same period in fiscal 2025, mainly driven by higher operating expenses, including non-recurring items, and a gain on the divestiture of a business in the prior year, partially offset by growth in revenues and a lower share count.
• Adjusted diluted EPS increased 11.6% to $4.52 compared with $4.05 in the prior year period, driven by growth in revenues and a lower share count.
• Net cash provided by operating activities was $204.7 million for the fourth quarter of fiscal 2026, a decrease of 3.5% compared with the prior year period.
• Free cash flow was $177.3 million for the fourth quarter of fiscal 2026, a decrease of 0.5% compared with the prior year period.
• GAAP effective tax rate decreased to 16.1% compared with 18.7% for the prior year period primarily due to the favorable resolution of uncertain tax positions in the U.S.

Full Year Fiscal 2026 Highlights

• GAAP revenues increased 6.7% or $154.5 million to $2.48 billion. This result continues FactSet’s track record of 47 consecutive years of increased revenues for the Company.
• GAAP operating margin was 28.3% compared with 32.2% for the prior year, primarily due to higher employee compensation costs, mainly driven by one-time restructuring charges, ASV-linked incentive plans and one-time CEO compensation costs, partially offset by growth in revenues.
• Adjusted operating margin was 34.5% compared with 36.3% in the prior year, mainly due to higher compensation expense from ASV-linked incentive plans and technology expenses.
• GAAP diluted EPS was $14.57 compared with $15.55 in the prior year period, mainly driven by higher operating expenses, including non-recurring items, partially offset by growth in revenues and a lower share count.
• Adjusted diluted EPS increased 6.1% to $18.01, primarily driven by growth in revenues and a lower share count. Fiscal 2026 marks the 30th consecutive year that FactSet has increased its adjusted diluted EPS.
• Net cash provided by operating activities was $822.2 million for fiscal 2026, an increase of 13.2% compared with the prior year period.
• Free cash flow was $707.5 million for fiscal 2026, an increase of 14.6% compared with the prior year period.
• GAAP effective tax rate increased to 17.9% compared with 17.2% for the prior year period primarily due to a stock-based compensation tax shortfall and the limitation on the deductibility of executive compensation, partially offset by the favorable resolution of uncertain tax positions in the U.S.

Annual Subscription Value (ASV)

ASV at any given point in time represents the forward-looking revenues for the next 12 months from all subscription services currently supplied to clients. Organic ASV at any point in time equals our ASV excluding ASV from acquisitions and the comparable impact of dispositions and discontinued lines of business effected within the last 12 months and the impact of foreign currency movements.

ASV was $2,565.2 million at August 31, 2026, compared with $2,405.6 million at August 31, 2025. Organic ASV was $2,568.2 million at August 31, 2026, up $168.2 million from the prior year, for a growth rate of 7.0%.

Segment Revenues and ASV

(Results in millions)	Aug. 31, 2026 ASV		Aug. 31, 2025 ASV		Aug. 31, 2026 Organic ASV		Organic ASV Growth	Q4 FY26 Revenues		Q4 FY25 Revenues		Organic Revenues Growth
Americas	$1,678.2		$1,570.1		$1,678.2		7.1%	$414.3		$388.7		6.7%
EMEA	$620.9		$591.6		$623.6		5.2%	$154.8		$147.4		6.6%
APAC	$266.1		$243.9		$266.4		10.6%	$65.6		$60.8		11.0%

Share Repurchase Program

FactSet repurchased 552,064 shares of its common stock for $138.0 million at an average price of $249.90 during the fourth quarter of fiscal 2026 under the Company’s share repurchase program. As of August 31, 2026, $356.0 million remained available for share repurchases under this program.

Annual Business Outlook

Fiscal 2027 Expectations:

Metric	Guidance
Organic ASV Growth	5.0% – 6.5%
Revenues	$2,600 – $2,625 million
	GAAP	Adjusted
Operating Margin	31.0% – 32.0%	34.75% – 35.25%
Diluted EPS	$17.00 – $17.50	$19.25 – $19.65

Adjusted operating margin and adjusted diluted EPS guidance do not include certain effects of any non-recurring benefits or charges that may arise in fiscal 2027. Please see the back of this press release for a reconciliation of GAAP to adjusted metrics.

Conference Call

Fourth Quarter 2026 Conference Call Details

Date:	Wednesday, September 30, 2026
Time:	9:00 a.m. Eastern Time
Participant Registration:	FactSet Q4 2026 Earnings Call Registration

Please register for the conference call using the above link in advance of the call start time. Upon registration, you will receive dial-in information and a unique access PIN. The earnings presentation will be available on FactSet’s Investor Relations website at 8:30 a.m. Eastern Time on September 30, 2026, 30 minutes before the earnings call begins.

A replay will be available on the Investor Relations website after 1:00 p.m. Eastern Time on September 30, 2026, and will remain accessible through September 30, 2027. A transcript of the earnings call will be available via FactSet CallStreet.

Forward-looking Statements

This press release contains forward-looking statements based on management’s current expectations, estimates, forecasts and projections about future events, trends, contingencies, and circumstances, industries in which FactSet operates and the beliefs and assumptions of management. All statements that address expectations, guidance, outlook or projections about the future, including statements about the Company’s strategy, product development, revenues, future financial results, anticipated growth, market position, subscriptions, expected expenditures or investments, trends in FactSet’s business and financial results, are forward-looking statements. Forward-looking statements may be identified by words like “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “intends,” “projects,” “indicates,” “predicts,” “potential,” or “continue,” the negative of those terms, and similar expressions. Forward-looking statements are not guarantees of future performance, outcomes, events, or actions and involve a number of known and unknown risks, uncertainties, and assumptions. Many factors, including those discussed more fully elsewhere in this release and in FactSet’s filings with the Securities and Exchange Commission, particularly its latest annual report on Form 10-K, including Item 1A, Risk Factors, and quarterly reports on Form 10-Q, as well as others, could cause results, performance, achievements, or activities to differ materially from those expressed or implied by the forward-looking statements. Accordingly, the Company cautions readers not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. FactSet assumes no duty to and does not undertake to update or revise any forward-looking statement to reflect events or circumstances arising after the date on which it is made, except as required by applicable law. Future results could differ materially from historical performance.

About Non-GAAP Financial Measures

The Company reports its financial results in accordance with U.S. GAAP. The Company also refers to and presents certain additional non-GAAP financial measures. These measures include: organic revenues, adjusted operating margin, adjusted operating income, adjusted net income, EBITDA, adjusted EBITDA, adjusted diluted EPS, and free cash flow. The Company has included reconciliations of these non-GAAP financial measures to the most directly comparable financial measures calculated in accordance with GAAP at the back of this release.

FactSet uses these non-GAAP financial measures both in presenting its results to stockholders and the investment community and in its internal evaluation and management of the business. The Company believes that these non-GAAP financial measures provide useful supplemental information to investors because they permit investors to view the Company’s performance using the same tools that management uses to gauge progress in achieving its goals. Investors may benefit from referring to these non-GAAP financial measures in assessing the Company’s performance and when planning, forecasting and analyzing future periods, and such measures may also facilitate comparisons to historical performance. The Company believes that organic revenues, adjusted operating margin, adjusted operating income, adjusted net income, EBITDA, adjusted EBITDA, and adjusted diluted EPS help to fully reflect the underlying economic performance of FactSet. The Company believes that free cash flow is useful to investors because it is an indication of cash flow that may be available to pay debt obligations, make strategic acquisitions and investments, pay dividends, repurchase stock, and strengthen the balance sheet. The presentation of this non-GAAP financial information should not be considered in isolation from, or as a substitute for, the financial information prepared and presented in accordance with GAAP. We are not able to provide reconciliations of certain forward-looking non-GAAP financial measures to comparable GAAP measures because certain items required for such reconciliations are outside of our control and/or cannot be reasonably predicted without unreasonable effort.

About FactSet

FactSet (NYSE: FDS | NASDAQ: FDS) supercharges financial intelligence, offering enterprise data and information solutions that help our clients maximize their potential. Our digital platform seamlessly integrates proprietary data, third-party sources, and flexible technology to deliver tailored solutions across the buy side, sell side, wealth, and corporate sectors. With over 48 years of expertise, we leverage advanced data connectivity, AI, and next-generation tools to streamline workflows and enable smarter decision-making. As an S&P 500 company serving more than 9,200 global clients and over 260,000 individual users, we are dedicated to innovation and long-term client success. Learn more at www.factset.com and follow us on X and LinkedIn.

Investor Relations:                         
Kevin Toomey
+1.212.209.5259
Kevin.Toomey@factset.com

Media Relations:
Adam Dalezman
+1.203.810.1035
media_request@factset.com

                                

Consolidated Statements of Income(Unaudited)
	Three Months Ended							Twelve Months Ended
	August 31,							August 31,
(In thousands, except per share data)		2026			2025				2026				2025
Revenues	$	634,698		$	596,901			$	2,476,256			$	2,321,748
Operating expenses
Cost of services		326,298			288,670				1,223,146				1,097,782
Selling, general and administrative		151,776			130,910				553,153				475,663
Total operating expenses		478,074			419,580				1,776,299				1,573,445
Operating income		156,624			177,321				699,957				748,303
Other income (expense), net
Interest income		1,442			2,050				4,064				6,533
Interest expense		(14,398	)		(12,886	)			(54,684	)			(56,324	)
Other income (expense), net		703			22,466				379				22,446
Total other income (expense), net		(12,253	)		11,630				(50,241	)			(27,345	)
Income before income taxes		144,371			188,951				649,716				720,958
Provision for income taxes		23,244			35,335				116,235				123,918
Net income	$	121,127		$	153,616			$	533,481			$	597,040
Basic earnings per common share	$	3.42		$	4.07			$	14.63			$	15.74
Diluted earnings per common share	$	3.41		$	4.03			$	14.57			$	15.55
Basic weighted average common shares		35,403			37,757				36,467				37,924
Diluted weighted average common shares		35,572			38,158				36,612				38,385

Consolidated Balance Sheets(Unaudited)
(In thousands)	August 31, 2026		August 31, 2025
ASSETS
Cash and cash equivalents	$	233,339	$	337,651
Investments		31,993		17,445
Accounts receivable, net of reserves of $13,584 at August 31, 2026 and $13,789 at August 31, 2025		301,439		270,684
Prepaid taxes		11,406		33,600
Prepaid expenses and other current assets		76,536		70,379
Total current assets		654,713		729,759
Property, equipment and leasehold improvements, net		79,246		85,203
Goodwill		1,283,025		1,284,708
Intangible assets, net		1,849,510		1,916,102
Deferred tax assets		74,550		61,226
Lease right-of-use assets, net		113,275		121,776
Other assets		88,524		105,498
TOTAL ASSETS	$	4,142,843	$	4,304,272
LIABILITIES
Accounts payable and accrued expenses	$	136,104	$	135,262
Current debt		499,436		—
Current lease liabilities		34,253		33,145
Accrued compensation		192,352		130,596
Deferred revenues		184,264		167,852
Current taxes payable		5,012		13,041
Dividends payable		40,901		41,410
Total current liabilities		1,092,322		521,306
Long-term debt		870,586		1,368,260
Deferred tax liabilities		11,279		14,902
Taxes payable		25,502		45,095
Long-term lease liabilities		138,139		157,104
Other liabilities		3,149		11,192
TOTAL LIABILITIES	$	2,140,977	$	2,117,859
STOCKHOLDERS’ EQUITY
TOTAL STOCKHOLDERS’ EQUITY	$	2,001,866	$	2,186,413
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	4,142,843	$	4,304,272

Certain prior year figures have been conformed to the current year’s presentation.

Consolidated Statements of Cash Flows (Unaudited)
	Twelve Months Ended
	August 31,
(In thousands)		2026			2025
CASH FLOWS FROM OPERATING ACTIVITIES
Net income	$	533,481		$	597,040
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation and amortization		180,830			157,691
Amortization of lease right-of-use assets		32,268			30,982
Stock-based compensation expense		84,099			61,229
Deferred income taxes		(14,284	)		(3,545	)
Gain on divestiture of a business		—			(23,238	)
Other, net		17,415			11,867
Changes in assets and liabilities, net of effects of acquisitions
Accounts receivable		(37,387	)		(42,540	)
Prepaid expenses and other assets		(2,209	)		65
Accounts payable and accrued expenses		(4,405	)		(59,400	)
Accrued compensation		62,553			35,666
Deferred revenues		15,813			2,249
Taxes payable, net of prepaid taxes		(5,079	)		(1,161	)
Lease liabilities, net		(40,895	)		(40,645	)
Net cash provided by operating activities		822,200			726,260
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property, equipment, leasehold improvements and capitalized internal-use software		(114,720	)		(108,806	)
Acquisition of businesses, net of cash and cash equivalents acquired		—			(348,255	)
Purchases of investments		(53,834	)		(18,867	)
Proceeds from maturity or sale of investments		36,050			58,155
Proceeds from divestiture		—			25,000
Net cash provided by (used in) investing activities		(132,504	)		(392,773	)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from debt		240,933			803,410
Repayments of debt		(242,500	)		(805,000	)
Dividend payments		(164,184	)		(159,973	)
Proceeds from employee stock plans		33,289			81,688
Repurchases of common stock		(643,961	)		(300,457	)
Deferred acquisition consideration		(15,327	)		(10,199	)
Other financing activities		(7,697	)		(17,290	)
Net cash provided by (used in) financing activities		(799,447	)		(407,821	)
Effect of exchange rate changes on cash, cash equivalents and restricted cash		(2,309	)		3,050
Net increase (decrease) in cash, cash equivalents and restricted cash		(112,060	)		(71,284	)
Cash, cash equivalents and restricted cash at beginning of period		351,695			422,979
Cash, cash equivalents and restricted cash at end of period	$	239,635		$	351,695
Reconciliation of total cash, cash equivalents and restricted cash:
Cash and cash equivalents	$	233,339		$	337,651
Restricted cash included in Prepaid expenses and other current assets		6,296			6,522
Restricted cash included in Other assets		—			7,522
Total cash, cash equivalents and restricted cash	$	239,635		$	351,695

Certain prior year figures have been conformed to the current year’s presentation.

Reconciliation of U.S. GAAP Results to Adjusted Financial Measures

Organic Revenues

Organic revenues exclude the current year impact of revenues from acquisitions and the comparable impact of dispositions and discontinued lines of business, effected within the past 12 months and the current year impact of foreign currency movements. The table below provides a reconciliation of revenues to organic revenues:

(Unaudited)	Three Months Ended								Twelve Months Ended
	August 31,								August 31,
(In thousands)		2026		2025		Change				2026			2025		Change
Revenues	$	634,698	$	596,901		6.3	%		$	2,476,256		$	2,321,748		6.7	%
Acquisition revenues		—		—						(10,066	)		—
Disposition revenues		—		(3,398	)					—			(12,461	)
Currency impact		845		—						(1,576	)		—
Organic revenues	$	635,543	$	593,503		7.1	%		$	2,464,614		$	2,309,287		6.7	%

Non-GAAP Financial Measures

The table below provides a reconciliation of operating income, operating margin, net income and diluted EPS to adjusted operating income, adjusted operating margin, adjusted net income, EBITDA, adjusted EBITDA, and adjusted diluted EPS.

Adjusted operating income and margin, adjusted net income, and adjusted diluted earnings per share exclude acquisition-related intangible asset amortization and non-recurring items. EBITDA represents earnings before interest expense, provision for income taxes and depreciation and amortization expense, while adjusted EBITDA further excludes non-recurring non-cash expenses.

	Three Months Ended									Twelve Months Ended
	August 31,									August 31,
(in thousands, except per share data)		2026			2025		% Change				2026			2025		% Change
Operating income	$	156,624		$	177,321		(11.7)%			$	699,957		$	748,303		(6.5)%
Intangible asset amortization		18,875			19,136						76,205			73,036
Restructuring/severance		26,899			576						46,200			259
CEO onboarding costs(1)		4,565			1,675						19,521			1,675
Business disposition, acquisitions and related costs		1,780			2,993						8,255			17,761
India labor codes reform		—			—						2,883			—
Asset impairment		—			—						887			—
Client bankruptcy charges		—			—						750			—
Litigation reserve		650			—						650			—
Sales tax dispute(2)		—			—						—			2,398
Adjusted operating income	$	209,393		$	201,701		3.8	%		$	855,308		$	843,432		1.4	%
Operating margin		24.7	%		29.7	%					28.3	%		32.2	%
Adjusted operating margin(3)		33.0	%		33.8	%					34.5	%		36.3	%
Net income	$	121,127		$	153,616		(21.1)%			$	533,481		$	597,040		(10.6)%
Intangible asset amortization		14,142			16,301						58,762			54,074
Restructuring/severance		20,154			491						35,625			192
CEO onboarding costs(1)		3,420			1,427						15,053			1,240
Impairment within Other assets(4)		—			—						12,338			—
Business disposition, acquisitions and related costs		1,334			2,550						6,365			13,150
India labor codes reform		—			—						2,223			—
Asset impairment		—			—						684			—
Client bankruptcy charges		—			—						578			—
Litigation reserve		487			—						501			—
Sales tax dispute(2)		—			—						—			1,775
Gain on business divestiture		—			(19,795	)					—			(17,205	)
Gain on sale of investments		—			—						(5,015	)		—
Non-operating income from business disposition		(136	)		—						(604	)		—
Income tax items		359			—						(493	)		1,351
Adjusted net income(5)	$	160,887		$	154,590		4.1	%		$	659,498		$	651,617		1.2	%
Net income	$	121,127		$	153,616		(21.1)%			$	533,481		$	597,040		(10.6)%
Interest expense		14,398			12,886						54,684			56,324
Income taxes		23,244			35,335						116,235			123,918
Depreciation and amortization expense		47,123			42,718						180,830			157,691
EBITDA	$	205,892		$	244,555		(15.8)%			$	885,230		$	934,973		(5.3)%
Non-recurring non-cash expenses(6)		3,320			—						26,177			—
Adjusted EBITDA	$	209,212		$	244,555		(14.5)%			$	911,407		$	934,973		(2.5)%
Diluted EPS	$	3.41		$	4.03		(15.4)%			$	14.57		$	15.55		(6.3)%
Intangible asset amortization		0.40			0.43						1.60			1.41
Restructuring/severance		0.57			0.01						0.97			0.01
CEO onboarding costs(1)		0.09			0.03						0.41			0.03
Impairment within Other assets(4)		—			—						0.34			—
Business disposition, acquisitions and related costs		0.04			0.07						0.18			0.34
India labor codes reform		—			—						0.06			—
Asset impairment		—			—						0.02			—
Client bankruptcy charges		—			—						0.02			—
Litigation reserve		0.01			—						0.01			—
Sales tax dispute(2)		—			—						—			0.05
Gain on business divestiture		—			(0.52	)					—			(0.45	)
Gain on sale of investments		—			—						(0.14	)		—
Non-operating income from business disposition		(0.01	)		—						(0.02	)		—
Income tax items		0.01			—						(0.01	)		0.04
Adjusted diluted EPS(5)	$	4.52		$	4.05		11.6	%		$	18.01		$	16.98		6.1	%
Weighted average common shares (diluted)		35,572			38,158						36,612			38,385

(1)	For fiscal 2026, these costs are related to the recognition, over their respective service periods, of one-time make-whole cash and equity awards issued to our CEO.
(2)	Related to a resolved matter with the Massachusetts Department of Revenue.
(3)	Adjusted operating margin is calculated as Adjusted operating income divided by Revenues.
(4)	Related to the impairment of an equity investment.
(5)	For purposes of calculating Adjusted net income and Adjusted diluted EPS, all adjustments for the three months ended August 31, 2026 and August 31, 2025, were taxed at an adjusted tax rate of 25.1% and 14.8%, respectively. The twelve months ended August 31, 2026 and August 31, 2025, were taxed at an adjusted tax rate of 22.9% and 26.0%, respectively.
(6)	Primarily related to the impairment of an equity investment and the recognition, over their respective service periods, of one-time equity awards issued to our CEO.

Business Outlook Reconciliation

(Unaudited)
Figures may not foot due to rounding	Annual Fiscal 2027 Guidance
(In millions, except per share data)
Revenues	$2,600 – $2,625
Operating income	$806 – $840
Operating margin	31.0% – 32.0%
Amortization of intangible assets and other discrete items	$85 – $97
Adjusted operating income	$903 – $925
Adjusted operating margin(a)	34.75% – 35.25%
Diluted earnings per share per common share	$17.00 – $17.50
Amortization of intangible assets and other discrete items	$2.15 – $2.25
Adjusted diluted earnings per common share	$19.25 – $19.65

(a)   Adjusted operating margin is calculated as Adjusted operating income divided by Revenues.

Free Cash Flow

Cash flows provided by operating activities have been reduced by purchases of property, equipment, leasehold improvements and capitalized internal-use software to report non-GAAP free cash flow.

(Unaudited)	Three Months Ended								Twelve Months Ended
	August 31,								August 31,
(In thousands)		2026			2025		Change			2026			2025		Change
Net Cash Provided for Operating Activities	$	204,708		$	212,100		(3.5)%		$	822,200		$	726,260		13.2	%
Less: purchases of property, equipment, leasehold improvements and capitalized internal-use software		(27,401	)		(33,966	)	(19.3)%			(114,720	)		(108,806	)	5.4	%
Free Cash Flow	$	177,307		$	178,134		(0.5)%		$	707,480		$	617,454		14.6	%

Organic ASV

The following table presents the calculation of organic ASV.

(In millions)	As of August 31, 2026
As reported ASV	$	2,565.2
Impact from foreign currency movements		3.0
Organic ASV	$	2,568.2
Organic ASV annual growth rate(a)		7.0	%

(a)	For comparability purposes, in calculating the organic ASV annual growth rate, the prior year excludes ASV from dispositions and discontinued lines of business effected within the last 12 months.

– Ribupatide injection (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of 35 kg/m² or higher

– Topline data now expected in mid-2028

WALTHAM, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) — Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the completion of enrollment in the KaiNETIC global Phase 3 clinical program. The KaiNETIC program, which encompasses three trials – KaiNETIC-1, KaiNETIC-2, and KaiNETIC-3 – is evaluating ribupatide injection (also known as KAI-9531), an investigational once-weekly dual GLP-1/GIP receptor agonist peptide, for the treatment of people living with obesity or overweight.

Topline data from KaiNETIC-1, KaiNETIC-2, and KaiNETIC-3 are now expected in mid-2028.

“Obesity is a complex, chronic disease, and millions of people still struggle to find a treatment that meets their needs,” said Scott Wasserman, M.D., Chief Medical Officer, Kailera. “Completing enrollment across all three KaiNETIC trials is an important milestone that brings us one step closer to delivering ribupatide injection to patients as a potential best-in-class medicine.”

About the KaiNETIC Phase 3 Program

KaiNETIC is a global Phase 3 program consisting of three double-blind, randomized, placebo-controlled Phase 3 clinical trials designed to evaluate the efficacy and safety of ribupatide injection for the treatment of obesity or overweight. The trials evaluate ribupatide doses up to 10 mg administered by weekly subcutaneous injection over a period of 76 weeks, with dose titration for up to 24 weeks and a maintenance dose of at least 52 weeks. Participants were enrolled at more than 200 investigative sites across eleven countries in North America, Europe, the United Kingdom, Oceania, and South America.

KaiNETIC-1 enrolled approximately 2,500 adults with a BMI of 30 kg/m² or greater, or a BMI of 27 kg/m² or greater with a comorbidity, excluding type 2 diabetes. The primary endpoint is percentage change in body weight from baseline at Week 76.

KaiNETIC-2 enrolled approximately 1,200 adults with a BMI of 27 kg/m² or greater and type 2 diabetes. The co-primary endpoints of this trial are percentage change in body weight from baseline at Week 76 and change in hemoglobin A1c from baseline at Week 76.

KaiNETIC-3 enrolled approximately 1,200 adults with a BMI of 35 kg/m² or greater and without type 2 diabetes. The co-primary endpoints of this trial are percentage change in body weight from baseline compared to placebo at Week 76 and percentage change in body weight from baseline compared to semaglutide 2.4 mg at Week 76.

In KaiNETIC-1 and KaiNETIC-2, participants were randomized to one of five arms – ribupatide 4 mg, 6 mg, 8 mg or 10 mg, or placebo, and both trials will also evaluate ribupatide in a pre-defined subgroup of participants with a BMI of 35 kg/m² or greater. In KaiNETIC-3, participants were randomized to one of four arms – ribupatide 8 mg or 10 mg, placebo, or open-label semaglutide 2.4 mg.

About Ribupatide

Ribupatide is a GLP-1 (glucagon-like peptide-1)/GIP (glucose-dependent insulinotropic polypeptide) receptor dual agonist peptide being developed as a once-weekly subcutaneous injection and as a once-daily oral pill for the treatment of obesity and overweight. Once-weekly ribupatide injection has been studied in more than 3,000 clinical trial participants who have been dosed with treatment out to 52 weeks, including in multiple late-stage clinical trials conducted by Hengrui in China. Hengrui submitted an NDA to the National Medical Products Administration (NMPA) in China for long-term weight management in adults. In May 2024, Hengrui granted Kailera exclusive global rights outside Greater China to develop, manufacture and commercialize its portfolio of innovative GLP-1 therapeutics, including ribupatide injection and ribupatide oral. Kailera is currently evaluating ribupatide injection for the treatment of obesity in the KaiNETIC global Phase 3 clinical program. Based on compelling clinical data to date, Hengrui is advancing once-daily ribupatide oral to Phase 3 clinical trials in China, and Kailera plans to initiate planned global Phase 3 trials in obesity in the first half of 2027.

About Kailera Therapeutics

Kailera Therapeutics (Kailera) is a clinical-stage biotechnology company focused on elevating the next era of obesity care by progressing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. With an obesity-first focus, Kailera is advancing four clinical-stage product candidates leveraging multiple GLP-1-based mechanisms of action and routes of administration specifically designed to address critical needs in the current therapeutic landscape with a lead product candidate, ribupatide injection (also known as KAI-9531), that has the potential for the greatest weight loss. Ribupatide injection is in global Phase 3 trials as a once-weekly injectable GLP-1/GIP receptor dual agonist. Kailera is expanding the ribupatide franchise by developing a once-daily oral formulation with the goal of providing an oral option with the potential for compelling weight loss and highly differentiated tolerability. Additionally, Kailera is advancing the development of KAI-7535, a once-daily oral small molecule GLP-1 receptor agonist, and KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera’s vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives. Kailera is based in Waltham, MA. For more information, visit www.kailera.com and follow us on LinkedIn and X.

Special Note Regarding Kailera Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the profile of product candidates, the potential of Kailera’s portfolio, the timing, design and outcome of research and development activities, including with respect to the timing of initiation and completion of clinical trials and the design and goals of clinical trials, market opportunities for product candidates, and the competitive landscape. Forward-looking statements can be identified by terms such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “suggest,” “plan,” “goal,” “vision,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” or similar expressions and the negatives of those terms. Kailera cannot assure you that the forward-looking statements in this press release will prove to be accurate. Information in this press release may also include statements relating to past performance, which should not be regarded as a reliable indicator of future performance. Forward-looking statements are based on current expectations and assumptions together with projections of the future which are inherently uncertain, and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks and uncertainties include, among others, uncertainties inherent in clinical development, regulatory review, manufacturing, competition, market opportunities, reliance on third parties, estimates of capital requirements, needs for additional financing, and other important factors, including those discussed under the caption “Risk Factors” in Kailera’s filings with the Securities and Exchange Commission. These statements speak only as of the date of this press release, and Kailera undertakes no obligation to update or revise any forward-looking statements. Kailera may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on these forward-looking statements.

Contact Information

Maura Gavaghan 
Vice President, Investor Relations 
maura.gavaghan@kailera.com

Anna Robinson
Vice President, Communications
anna.robinson@kailera.com

Three Orders for 10 Production Systems Combine to Represent Largest Order in Company History

Record Orders Significantly Increase Fiscal 2028 Revenue Visibility

MILTON, N.Y., Sept. 30, 2026 (GLOBE NEWSWIRE) — Sono-Tek Corporation (Nasdaq: SOTK), the leading developer and manufacturer of ultrasonic coating systems, today announced that it has received three purchase orders totaling approximately $7.19 million from an existing customer in the clean energy sector. The orders include 10 production-scale coating systems for shipment to three different geographic locations and represent the largest aggregate customer order in Sono-Tek’s history.

The orders continue a multi-year relationship with a customer that has successfully installed and operated Sono-Tek production systems for its advanced solar manufacturing process. The latest orders represent a significant expansion of the customer’s use of Sono-Tek’s proprietary ultrasonic coating technology and further demonstrate the progression of Sono-Tek systems from process development into high volume manufacturing applications.

The 10 systems are currently expected to be delivered primarily during Sono-Tek’s 2028 fiscal year, which begins on March 1, 2027. Actual delivery timing may vary based on production schedules and customer requirements.

The new orders add significant clarity to Sono-Tek’s probable fiscal 2028 revenue. Together with the previously announced medical diagnostic production line order of more than $3.6 million, Sono-Tek now has more than $10.79 million in backlog from these two programs, with the majority currently expected to ship during fiscal 2028. With approximately five months remaining before fiscal 2028 begins, Sono-Tek has additional time to build even further upon this backlog. The two programs serve different customers in two key growth markets—alternative energy and medical devices.

Steve Harshbarger, President and CEO of Sono-Tek, commented: “These record orders represent an important milestone for Sono-Tek and a significant expansion of our relationship with this customer. Following the successful deployment of our technology in its advanced clean energy manufacturing process, the customer is now expanding its use of Sono-Tek production systems across three geographic locations.”

“The size and scope of these orders demonstrate the significant opportunity created when customers successfully scale a proven process using Sono-Tek technology. They are also a strong example of our long-term growth strategy: supporting customers from process development through high-volume manufacturing with increasingly sophisticated production systems and higher average selling prices.”

“Together with the more than $3.6 million medical diagnostic production line announced in August, we now have more than $10.79 million in backlog from these two programs that is currently expected to be delivered primarily during fiscal 2028. Importantly, these two major programs are for different customers serving two distinct markets. With approximately five months remaining before fiscal 2028 begins, we believe this provides significant early visibility into the coming fiscal year, while providing additional time to further build our fiscal 2028 backlog.”

The latest orders continue to reinforce Sono-Tek’s position in the alternative energy sector, a key component of the Company’s long-term growth strategy. Sono-Tek’s ultrasonic coating systems are being used in a growing range of clean energy applications, including next-generation solar cells, fuel cells, green hydrogen generation and carbon capture.

About Sono-Tek

Sono-Tek Corporation is the global leader in the design and manufacture of ultrasonic coating systems that are shaping industries and driving innovation worldwide. Our ultrasonic coating systems are used to apply thin films onto parts used in diverse industries, including microelectronics, alternative energy, medical devices, advanced industrial manufacturing, and research and development sectors worldwide. Sono-Tek’s inroads into the clean energy sector are showing transformative results in next-generation solar cells, fuel cells, green hydrogen generation, and carbon capture
applications.

Our product line is rapidly evolving, transitioning from R&D to high-volume production machines with significantly higher average selling prices. Our comprehensive suite of thin film coating solutions and application consulting services helps customers achieve technological breakthroughs and successfully scale manufacturing from concept through production. We strategically deliver our products through a network of direct sales personnel, carefully chosen independent distributors, and experienced sales representatives, ensuring efficient market reach across diverse industries
worldwide.

Our solutions are environmentally friendly, efficient, and highly reliable, enabling dramatic reductions in overspray while reducing raw material, water, and energy consumption. They provide improved process repeatability, high transfer efficiency, exceptional coating uniformity, and reduced emissions.

Sono-Tek’s growth strategy is focused on leveraging its innovative technologies, proprietary know-how, unique talent and experience, and global reach to further develop thin film coating technologies that enable better outcomes for its customers’ products and manufacturing processes.

Safe Harbor Statement 

This news release contains forward-looking statements regarding future events and the future performance of Sono-Tek Corporation that involve risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are based on currently available competitive, financial, and economic data and our operating plans. They are inherently uncertain, and investors must recognize that events could turn out to be significantly different from our expectations and could cause actual results to differ materially. These factors include, among other considerations, general economic and business conditions, including political, regulatory, tax, competitive, and technological developments affecting our operations or the demand for our products; inflationary and supply chain pressures; continued strength of sales to the medical device market; continued strong demand for Sono-Tek’s suite of thin film coating solutions and application consulting services in the clean energy and other markets; maintenance of order backlog; evolving tariff policies; timely development and market acceptance of new products and continued customer validation of our coating technologies; adequacy of financing; capacity additions; the ability to enforce patents; maintenance of operating leverage; consummation of order proposals; completion of large orders on schedule and on budget; successful transition from primarily selling ultrasonic nozzles and components to a more complex business providing complete machine solutions and higher-value subsystems; and realization of quarterly and annual revenues within the forecasted range of sales guidance. We undertake no obligation to update any forward-looking statement.

For More Information:

Sono-Tek Corporation
Stephen J. Bagley
Chief Financial Officer
Ph: (845) 795-2020
info@sono-tek.com

Investor Relations
Kirin Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com

TORONTO, Sept. 30, 2026 (GLOBE NEWSWIRE) — Northland Power Inc. (“Northland” or the “Company”) (TSX: NPI) today announced the close of approximately PLN 500 million (CAD 185 million) in project financing for its Mieczysławów (200 MW / 800 MWh) and Kamionka (100 MW / 400 MWh) battery energy storage system (“BESS”) projects in Poland, both of which are currently under construction.

The financing was secured with Canadian and Polish financial institutions and completes the funding structure for the projects. Both projects have also received grants totaling approximately PLN 280 million (CAD 105 million) from Poland’s National Fund for Environmental Protection and Water Management. Northland has already fulfilled its equity commitment for both projects using corporate cash and available funding. Total capital costs for Kamionka and Mieczysławów are estimated to be approximately PLN 1.0 billion (CAD 0.4 billion).

“Securing financing for Kamionka and Mieczysławów completes the funding structure for both projects and marks another important milestone in Northland’s growth in Poland,” said Jeff Hart, Chief Financial Officer of Northland Power. “These projects demonstrate our disciplined approach to capital allocation and our ability to execute on projects. As demand for flexible grid infrastructure continues to grow, battery storage is an important part of our portfolio and a key driver of long-term value creation.”   

Kamionka and Mieczysławów remain on track, with commercial operations expected in early 2028 and mid-2028, respectively. Once fully operational, the projects are expected to contribute approximately $40 million to $50 million of combined annual Adjusted EBITDA.

Acquired in November 2025 as late-stage, pre-construction projects, Northland has since advanced both projects through development, secured grant funding and project financing, and commenced construction. Together, the facilities will provide 300 MW / 1.2 GWh of battery storage capacity, with a portion of revenues contracted under 17-year inflation-indexed auction agreements and additional revenue opportunities through energy arbitrage and ancillary services markets.

Once operational, Kamionka and Mieczysławów are expected to be among the first utility-scale standalone battery storage facilities operating in Poland. Together with Baltic Power, the projects further strengthen the Company’s presence in one of its core growth markets. The facilities will support grid reliability, increase system flexibility and help integrate Poland’s growing renewable energy generation.

ABOUT NORTHLAND POWER

Northland Power is a Canadian-headquartered global power producer delivering the electricity the world needs through offshore wind, onshore renewables, battery storage, and natural gas-fired generation. With offices in seven countries, Northland owns, in whole or in part, 3.6 GW of gross operating generating capacity, 2.4 GW under construction, and an approximately 8 GW development pipeline, reflecting nearly four decades of experience delivering large-scale energy infrastructure. 

Publicly traded since 1997, Northland’s Common Shares, and Series 1 and Series 2 Preferred Shares trade on the Toronto Stock Exchange under the symbols NPI, NPI.PR.A and NPI.PR.B, respectively.

FORWARD LOOKING INFORMATION

This news release contains statements that constitute forward-looking information within the meaning of applicable securities laws (“forward-looking statements”) that are provided for the purpose of presenting information about management’s current expectations and plans. Readers are cautioned that such statements may not be appropriate for other purposes. Northland’s actual results could differ materially from those expressed in, or implied by, these forward-looking statements and, accordingly, the events anticipated by the forward-looking statements may or may not transpire or occur. Forward-looking statements include statements that are predictive in nature, depend upon or refer to future events or conditions, or include words such as “anticipates”, “expects,” “believes,” or negative versions thereof and other similar expressions or future or conditional verbs such as “may,” “will,” “should,” “would” and “could.” These statements may include, without limitation, statements regarding Northland’s expectations for the timing of commercial operations and the capital cost expectations for the Projects, the expected scale of the Projects and its anticipated capacity to generate renewable electricity, the expected sufficiency of funding to cover Project requirements, the contribution of the Projects to Northland’s Adjusted EBITDA and the size of Northland’s development pipeline, all of which may differ from the expectations stated herein. These statements are based upon certain material factors or assumptions that were applied in developing the forward-looking statements, including the provisions of contracts to which Northland or a subsidiary is a party, as well as other factors, estimates, and assumptions that are believed to be appropriate in the circumstances. Although these forward-looking statements are based upon management’s current reasonable expectations and assumptions, they are subject to numerous risks and uncertainties. Some of the factors include, but are not limited to, those described in the “Risks Factors” section of Northland’s Management’s Discussion and Analysis and Annual Information Form for the year ended December 31, 2025, which can be found at www.sedarplus.ca under Northland’s profile and on Northland’s website at northlandpower.com. Northland has attempted to identify important factors that could cause actual results to materially differ from current expectations, however, there may be other factors that cause actual results to differ materially from such expectations. Northland’s actual results could differ materially from those expressed in, or implied by, these forward-looking statements and, accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, and Northland cautions you not to place undue reliance upon any such forward-looking statements.

The forward-looking statements contained in this release are, unless otherwise indicated, stated as of the date hereof and are based on assumptions that were considered reasonable as of the date hereof. Other than as specifically required by law, Northland undertakes no obligation to update any forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or results, or otherwise.

NON-IFRS FINANCIAL MEASURES

This press release includes references to the Company’s adjusted earnings before interest, income taxes, depreciation and amortization (“Adjusted EBITDA”), Free Cash Flow and applicable payout ratios and per share amounts, which are measures not prescribed by International Financial Reporting Standards (“IFRS”), and therefore do not have any standardized meaning under IFRS and may not be comparable to similar measures presented by other companies. Non-IFRS financial measures are presented at Northland’s share of underlying operations. These measures should not be considered alternatives to net income (loss), cash flow from operating activities or other measures of financial performance calculated in accordance with IFRS. Instead, these measures are provided to complement IFRS measures in the analysis of Northland’s results of operations from management’s perspective. Management believes that Northland’s non-IFRS financial measures and applicable payout ratio and per share amounts are widely accepted and understood financial indicators used by investors and securities analysts to assess the performance of a company, including its ability to generate cash through operations.

For further information, please contact:

Alison Holditch, Head of Investor Relations
+ 1 (416) 989-8734 
investorrelations@northlandpower.com 

Victor Gravili, Vice President of Corporate Affairs 
+1 (416) 895-5433 
communications@northlandpower.com 

NASHVILLE, Tenn., Sept. 30, 2026 (GLOBE NEWSWIRE) — Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that 15 scientific abstracts featuring data from across its ophthalmic portfolio will be presented at two major eyecare meetings:

• American Academy of Optometry’s (AAOpt) Annual meeting taking place September 30 – October 3, 2026, in Anaheim, California; and
• American Academy of Ophthalmology’s (AAO) Annual Meeting, taking place October 9–12, 2026, in New Orleans, Louisiana.

Harrow will have 13 presentations at AAOpt 2026 and two at AAO 2026, spanning dry eye disease, vernal keratoconjunctivitis (VKC), ocular inflammation, chronic blepharitis, and post-operative inflammation and pain. The research includes Phase 3 trial results, pooled Phase 3 analyses, 52-week long-term safety data, a randomized, double-masked comparative study, real-world evidence, and systematic reviews and meta-analyses. Featured Harrow products include VEVYE®, VERKAZIA®, FLAREX®, and BYQLOVI®.

“Fifteen presentations across the two Academies reflect the breadth of Harrow’s ophthalmic portfolio and the growing body of clinical evidence supporting it,” said Amir Shojaei, PhD, PharmD, Chief Scientific Officer of Harrow. “We are committed to generating and sharing clinically relevant data that can help optometrists and ophthalmologists make informed treatment decisions for their patients.”

Presentation Details

Harrow’s scientific presentations are listed below.

American Academy of Optometry – AAOpt 2026 Anaheim September 30 – October 3, 2026  |  Anaheim Convention Center, Anaheim, CA  |  13 presentations  |  All times Pacific
Date / Time	Presentation Title	Presenter(s)	Product / Area
Thu., Oct. 1 4:30–6:30 p.m. Evening Poster Session	A Clinical Trial to Evaluate Corneal Endothelial Health Over 52 Weeks in Dry Eye Disease Patients Treated with Cyclosporine Ophthalmic Solution, 0.1%	Patrick Vollmer, OD	VEVYE® – Dry Eye Disease
Thu., Oct. 1 4:30–6:30 p.m. Evening Poster Session	Rapid Dryness Improvement with Cyclosporine 0.1% in Perfluorobutylpentane and Perfluorobutylpentane Alone in Dry Eye Disease: Pooled Subgroup Analysis	Milton Hom, OD	VEVYE® – Dry Eye Disease
Thu., Oct. 1 4:30–6:30 p.m. Evening Poster Session	Patient-Reported Blurred Vision Improvement with Cyclosporine 0.1%/PFBP in Dry Eye Disease with Severe Corneal Staining: Phase 3 Pool	Eric Schmidt, OD	VEVYE® – Dry Eye Disease
Thu., Oct. 1 4:30–6:30 p.m. Evening Poster Session	Real-World Improvement in Fluorescein TBUT with VEVYE in Severe Dry Eye Disease with Neuro-Ophthalmic Comorbidity	Faraz Haghighi, OD	VEVYE® – Dry Eye Disease
Thu., Oct. 1 4:30–6:30 p.m. Evening Poster Session	OSDI Responder Rates with Real-World VEVYE in a Severely Symptomatic Neuro-Ophthalmic Dry Eye Cohort	Faraz Haghighi, OD	VEVYE® – Dry Eye Disease
Thu., Oct. 1 4:30–6:30 p.m. Evening Poster Session	Safety of Cyclosporine A 0.1% Cationic Emulsion in Vernal Keratoconjunctivitis: Pooled NOVATIVE/VEKTIS with Prior-Antiallergic Subgroup	Kyle Klute, OD	VERKAZIA® – VKC
Thu., Oct. 1 4:30–6:30 p.m. Evening Poster Session	Course of Individual Symptom Relief with Cyclosporine A 0.1% Cationic Emulsion in Pediatric Severe Vernal Keratoconjunctivitis: VEKTIS Phase III Trial	Ruchita Shah, OD	VERKAZIA® – VKC
Thu., Oct. 1 4:30–6:30 p.m. Evening Poster Session	Steroid Rescue Reduction and Treatment Compliance in Pediatric Vernal Keratoconjunctivitis: Longitudinal Findings from the VEKTIS Phase 3 Trial	Andrew Royer, OD	VERKAZIA® – VKC
Thu., Oct. 1 4:30–6:30 p.m. Evening Poster Session	Topical Calcineurin Inhibitors in Pediatric Vernal Keratoconjunctivitis: A Systematic Review and Meta-Analysis of Cyclosporine A and Tacrolimus	Kaleb Abbott, OD	VERKAZIA® – VKC
Thu., Oct. 1 4:30–6:30 p.m. Evening Poster Session	Randomized, Double-Masked Comparison of Ocular Tolerability and Patient Preference for Fluorometholone Acetate Suspension vs. Loteprednol Etabonate Gel	Josh Davidson, OD	FLAREX® – Ocular Inflammation
Thu., Oct. 1 4:30–6:30 p.m. Evening Poster Session	Treatment Outcomes in Chronic Blepharitis Managed by Topical Prescription Therapies: A Systematic Review and Meta-Analysis	Selina McGee, OD Richard Adler, OD	Blepharitis – Disease State
Fri., Oct. 2 1:00–3:00 p.m. Poster Session	Early Symptom Relief with Cyclosporine A 0.1% Cationic Emulsion in Pediatric Vernal Keratoconjunctivitis: A Descriptive Analysis	Chris Jacquinot, OD Shane Kannarr, OD	VERKAZIA® – VKC
Fri., Oct. 2 1:00–3:00 p.m. Scientific Program / Residents Poster Session	Pediatric Ocular Comfort of Topical Cyclosporine A 0.05% and 0.1% Cationic Emulsion in Vernal Keratoconjunctivitis	Elsa Sheerer, OD	VERKAZIA® – VKC

American Academy of Ophthalmology – AAO 2026 Annual Meeting October 9–12, 2026  |  Ernest N. Morial Convention Center, New Orleans, LA  |  2 presentations  |  All times Central
Date / Time	Presentation Title	Presenter(s)	Product / Area
Sat., Oct. 10 9:15–10:15 a.m. Podium Poster PT03 – Cataract	Clobetasol Propionate for Post-Cataract Inflammation and Pain: Second Phase 3 Trial with Corneal Endothelial Cell Safety	Jason Bachrach, MD	BYQLOVI® – Post-Op Care
Poster on Demand Poster PO277	Clobetasol Propionate Nanosuspension for Post-Cataract Inflammation and Pain: First Pivotal Phase 3 Trial	Steven Silverstein, MD Eva Liang, MD	BYQLOVI® – Post-Op Care

VEVYE® (cyclosporine ophthalmic solution) 0.1%
Indications and Usage
VEVYE® (cyclosporine ophthalmic solution) 0.1% is indicated for the treatment of the signs and symptoms of dry eye disease.

Important Safety Information
WARNINGS AND PRECAUTIONS
Potential for Eye Injury and Contamination: To avoid the potential for eye injury and/or contamination, patients should not touch the bottle tip to the eye or other surfaces.

Use with Contact Lenses: VEVYE® should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following the administration of VEVYE®.

ADVERSE REACTIONS
In clinical trials with 738 subjects receiving at least 1 dose of VEVYE®, the most common adverse reactions were instillation site reactions (8%) and temporary decreases in visual acuity (3%).

Please see full Prescribing Information for VEVYE.

VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1%
Indications and Usage
Verkazia® (cyclosporine ophthalmic emulsion) 0.1% is a calcineurin inhibitor immunosuppressant indicated for the treatment of vernal keratoconjunctivitis in children and adults.

Important Safety Information
WARNINGS AND PRECAUTIONS
Potential for eye injury and contamination: To avoid the potential for eye injury and contamination, advise patient not to touch the vial tip to the eye or other surfaces.

ADVERSE REACTIONS
The most common adverse reactions reported in greater than 5% of patients were eye pain (12%) and eye pruritus (8%), which were usually transitory and occurred during instillation.

Please see full Prescribing Information for VERKAZIA.

FLAREX® (fluorometholone acetate ophthalmic suspension) 0.1%
Indications and Usage
FLAREX® (fluorometholone acetate ophthalmic suspension) 0.1% is indicated for use in the treatment of steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the eye.

Important Safety Information
CONTRAINDICATIONS
Contraindicated in acute superficial herpes simplex keratitis, vaccinia, varicella, and most other viral diseases of the cornea and conjunctiva; mycobacterial infection of the eye; fungal diseases; acute purulent untreated infections, which like other diseases caused by microorganisms, may be masked or enhanced by the presence of the steroid; and in those persons who have known hypersensitivity to any component of this preparation.

WARNINGS AND PRECAUTIONS
Topical Ophthalmic Use: Not for injection.

Intraocular Pressure Increase: Prolonged use may result in glaucoma, damage to the optic nerve, and defects in visual acuity and visual field. It is advisable that the intraocular pressure be checked frequently.

Cataracts: Use of corticosteroids may result in cataract formation.

Delayed Healing: Topical ophthalmic corticosteroids may slow corneal wound healing. In those diseases causing thinning of the cornea or sclera, perforation has been known to occur with chronic use of topical steroids.

Viral Infections: Use in the treatment of herpes simplex infection requires great caution.

Bacterial Infections: Use of corticosteroids may suppress the host response and thus aid in the establishment of secondary ocular infections. Acute purulent infections of the eye may be masked or exacerbated by the presence of steroid medication.

Fungal Infections: Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use.

Contamination: Do not touch dropper tip to any surface as this may contaminate the suspension.

Contact Lens Wear: Contact lenses should be removed during instillation of FLAREX but may be reinserted 15 minutes after instillation.

Temporarily Blurred Vision: Vision may be temporarily blurred following dosing with FLAREX. Care should be exercised in operating machinery or driving a motor vehicle.

ADVERSE REACTIONS
Glaucoma with optic nerve damage, visual acuity and field defects, cataract formation, secondary ocular infection following suppression of host response, and perforation of the globe may occur.

Post marketing Experience: The following reaction has been identified during post marketing use of FLAREX in clinical practice. Because reactions are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The reaction, which has been chosen for inclusion due to either its seriousness, frequency of reporting, possible causal connection to FLAREX, or a combination of these factors, includes dysgeusia. The following rare adverse reactions have been reported: Cushing’s syndrome and adrenal suppression may occur after very frequent use of topical ophthalmic corticosteroids, particularly in very young children.

Please see full Prescribing Information for FLAREX.

BYQLOVI® (clobetasol propionate ophthalmic suspension) 0.05%
Indications and Usage
BYQLOVI® (clobetasol propionate ophthalmic suspension) 0.05% is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery.

Important Safety Information
CONTRAINDICATIONS
BYQLOVI is contraindicated in most active viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures.

WARNINGS AND PRECAUTIONS
Intraocular Pressure (IOP) Increase: Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma. If BYQLOVI is used for 10 days or longer, IOP should be monitored.

Cataracts: Prolonged use of corticosteroids may result in posterior subcapsular cataract formation.

Delayed Healing: The use of corticosteroids after cataract surgery may delay healing and increase the incidence of bleb formation.

Corneal and Scleral Melting: In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical corticosteroids. The initial prescription and renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy, and where appropriate, fluorescein staining.

Bacterial Infections: Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions, steroids may mask infection or enhance existing infection. If signs and symptoms fail to improve after 2 days, the patient should be reevaluated.

Viral Infections: Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular corticosteroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex).

Fungal Infections: Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local corticosteroid application. Fungus invasion must be considered in any persistent corneal ulceration where a corticosteroid has been used or is in use. Fungal culture should be taken when appropriate.

Risk of Contamination: Do not allow the dropper tip to touch any surface, as this may contaminate the ophthalmic suspension.

Contact Lens Wear: BYQLOVI should not be instilled while wearing contact lenses. Remove contact lenses prior to instillation of BYQLOVI. The preservative in BYQLOVI may be absorbed by soft contact lenses. Lenses may be reinserted after 15 minutes following administration of BYQLOVI.

ADVERSE REACTIONS
Ocular adverse reactions occurring in ≥ 1% of subjects in clinical studies who received BYQLOVI included eye inflammation (2%), corneal edema (2%), anterior chamber inflammation (2%), cystoid macular edema (2%), intraocular pressure elevation (1%), photophobia (1%) and vitreous detachment (1%). Many of these reactions may have been the consequence of the surgical procedure.

Please see full Prescribing Information for BYQLOVI.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

About Harrow

Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and diseases of the retina. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com and connect with us on LinkedIn.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, risks related to: liquidity or results of operations; our ability to successfully implement our business plan, develop and commercialize our products, product candidates and proprietary formulations in a timely manner or at all, identify and acquire additional products, manage our pharmacy operations, service our debt, obtain financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of our previous acquisitions and any other acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical companies, outsourcing facilities and pharmacies; general economic and business conditions, including inflation and supply chain challenges; regulatory and legal risks and uncertainties related to our pharmacy operations and the pharmacy and pharmaceutical business in general, including the ongoing communications with the U.S. Food and Drug Administration relating to compliance and quality plans at our outsourcing facility in New Jersey; physician interest in and market acceptance of our current and any future formulations and compounding pharmacies generally. These and additional risks and uncertainties are more fully described in Harrow’s filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2025, and other filings with the SEC. Such documents may be read free of charge on the SEC’s web site at sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Harrow undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Investor & Media Contact:
Mike Biega
Vice President of Investor Relations and Communications
mbiega@harrowinc.com
617-913-8890

• JADE301 is designed to build on a clinically validated IFN-β mechanism with a differentiated profile designed for infrequent subcutaneous dosing
• JADE301 demonstrated high-affinity, selective IFN-β binding and greater functional potency than a dazukibart comparator in disease-relevant human cells
• Following subcutaneous administration in non-human primates, JADE301 was effectively half-life extended with an approximately 25-day half-life and predictable distribution into muscle
• JADE301 was well tolerated in non-human primates at all evaluated subcutaneous doses
• Phase 1 healthy volunteer trial expected to begin in the fourth quarter of 2026; interim data anticipated in the second half of 2027
• Company to host conference call and webcast today at 8:30 a.m. ET

SAN FRANCISCO and VANCOUVER, British Columbia, Sept. 30, 2026 (GLOBE NEWSWIRE) — Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced preclinical data characterizing JADE301, its potentially best-in-class, half-life-extended anti-interferon beta (IFN-β) monoclonal antibody in development for dermatomyositis (DM), a rare, chronic and debilitating autoimmune disease characterized by painful inflammatory skin disease and progressive muscle weakness. JADE301 is a fully human IgG1 monoclonal antibody with a YTE modification designed to selectively and potently neutralize IFN-β and inhibit downstream signaling implicated as a proximal driver in DM pathogenesis.

The data are being presented in an e-poster at the 2026 European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria (Poster #P1813).

“JADE301 was designed to leverage the clinically validated anti-IFN-β mechanism in dermatomyositis with a differentiated molecular and pharmacokinetic profile,” said Andrew King, Ph.D., President, Research & Development of Jade Biosciences. “These preclinical data support potent and selective IFN-β inhibition, and demonstrate pharmacokinetic properties characterized by an extended half-life, favorable subcutaneous bioavailability, and muscle distribution. These attributes support the development of a targeted, disease-modifying therapy that has the potential to provide durable improvement across both skin and muscle manifestations of dermatomyositis, while reducing treatment burden for patients through infrequent subcutaneous dosing.”

“For people living with dermatomyositis, the treatment goal is to control both skin and muscle disease activity, restore strength and daily function, and limit reliance on chronic steroids,” said Rohit Aggarwal, M.D., M.S., Professor of Medicine at University of Pittsburgh and Medical Director of Arthritis and Autoimmunity Center at University of Pittsburgh Medical Center. “Yet targeted treatment options remain limited, and many patients continue to experience substantial disease and treatment burden. The clinical validation of IFN-β as a therapeutic target represents a promising advance for the field. JADE301’s preclinical profile, including potent and selective IFN-β neutralization, extended half-life, and subcutaneous administration, supports clinical evaluation to assess if this approach can deliver durable disease control with a less burdensome treatment regimen.”

Summary of JADE301 Preclinical Data

High-affinity, selective and potent IFN-β neutralization

• JADE301 demonstrated high-affinity binding to IFN-β, with a K_D of 11.3 pM, approximately 2.5-fold higher affinity than a dazukibart comparator, and no detectable binding to other interferon family proteins.
• JADE301 potently inhibited downstream IFN-β signaling.
  • In a human immune cell line, JADE301 inhibited induction of pSTAT with an IC₅₀ of 13 pM, approximately 2.5-fold more potent than the dazukibart comparator.
  • Suppression of MX-1, a marker of IFN pathway activity relevant to DM, was demonstrated in human dermal fibroblasts, a disease-relevant skin cell type, and peripheral blood mononuclear cells; in human dermal fibroblasts, JADE301 inhibited MX-1 induction with an IC₅₀ of 11 pM, approximately 8-fold more potent than the dazukibart comparator.

Differentiated pharmacokinetic profile supports potential for infrequent subcutaneous dosing

• JADE301 demonstrated an approximately 30-day half-life following a 30 mg/kg intravenous dose in non-human primates (NHPs), approximately 3-fold longer than the dazukibart comparator.
• Following subcutaneous (SC) administration in NHPs, JADE301 demonstrated an approximately 25-day half-life. Translational modeling predicted human SC bioavailability of approximately 73%–75%, compared with a reported dazukibart SC bioavailability in humans of approximately 43%–44%, supporting the potential for convenient, infrequent SC dosing.
• JADE301 concentrations in muscle were consistent with the typical range reported for monoclonal antibodies, approximately 1%–4% of serum concentrations, providing a translational framework to inform dose selection and exposure at a key site of active disease in DM.

Favorable nonclinical tolerability profile

• In a GLP toxicology study in NHPs, subcutaneous JADE301 was administered every two weeks at doses of 0, 50, 100 and 200 mg/kg and was well tolerated at all dose levels evaluated.
• There were no treatment-related adverse clinical observations or meaningful adverse findings on laboratory or other standard safety assessments. No treatment-related histopathology findings were observed.

JADE301 Phase 1 Development

Jade expects to initiate a placebo-controlled, single ascending-dose Phase 1 trial evaluating subcutaneous JADE301 in 24 healthy volunteers in the fourth quarter of 2026, with interim data anticipated in the second half of 2027. The study is designed to assess safety and tolerability, and to characterize the pharmacokinetic and immunogenicity profile of JADE301.

Conference Call and Webcast

Jade will host a conference call and webcast today, September 30, 2026, at 8:30 a.m. ET to discuss the JADE301 profile outlined in this press release. Investors and the general public are invited to listen to the live webcast and may register on the “Events and Presentations” page of the company’s website at JadeBiosciences.com. To join the live conference call, participants must register here. Upon registering, you will receive dial-in details and a unique PIN to access the call. A replay of the webcast will be available for 90 days on the Jade website. 

About Dermatomyositis

Dermatomyositis (DM) is a rare, chronic autoimmune disease affecting approximately 50,000 adults in the U.S. and characterized by inflammatory skin disease, progressive muscle weakness and potentially serious systemic complications. Excessive type I interferon signaling is a hallmark of DM, with IFN-β believed to play a central role in driving inflammation in both skin and muscle. DM can substantially impair daily functioning, including the ability to walk, climb stairs, bend or lift, while painful skin disease and severe itching can further disrupt sleep and quality of life. Many patients continue to experience chronic disease activity despite treatment, underscoring the need for more effective, durable and less burdensome treatment options.

About JADE301

JADE301 is an investigational anti-IFN-β monoclonal antibody being developed for dermatomyositis. By selectively neutralizing IFN-β, a clinically validated target and key driver of disease pathology, JADE301 is designed to address both skin and muscle manifestations of DM. Engineered with half-life extension technology, JADE301 is being developed with the goal of delivering a convenient, infrequent subcutaneous administration, with the potential to provide durable disease control and reduce treatment burden.

About Jade Biosciences, Inc.

Jade Biosciences is a clinical-stage biotechnology company focused on developing best-in-class therapies that address critical unmet needs in autoimmune diseases. Jade’s lead candidate, JADE101, targets the cytokine APRIL, and is currently being evaluated for the treatment of immunoglobulin A nephropathy. Jade’s pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, as well as JADE301, an anti-IFN-β monoclonal antibody. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. For more information, visit JadeBiosciences.com and follow the Company on LinkedIn.

Forward-Looking Statements

Certain statements in this communication, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the “safe harbor” provisions under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements relating to Jade’s expectations, hopes, beliefs, intentions or strategies regarding the future of its pipeline and business including, without limitation: Jade’s ability to achieve the expected benefits or opportunities with respect to JADE101, JADE201 and JADE301 and their best-in-class potential; the expected timelines for the initiation of, and the availability of interim data from, the Phase 1 clinical trial of JADE301; the projected human bioavailability of JADE301; and the potential therapeutic uses, efficacy, durability, safety profiles, and dosing of JADE301. The words “opportunity,” “potential,” “milestones,” “pipeline,” “can,” “goal,” “strategy,” “target,” “anticipate,” “achieve,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “plan,” “possible,” “project,” “should,” “will,” “would” and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Jade will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Jade’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: the planned clinical trial of JADE301 and any other clinical trials may be delayed or may not demonstrate desirable efficacy or predicted performance; adverse events and safety signals may occur; modeled and predicted data may not be realized in actual clinical studies; Jade may experience unanticipated costs, difficulties or delays in the product development process; Jade’s product candidates may be delayed to a point where they are not commercially viable; clinical trial start up, enrollment or regulatory challenges may occur; challenges associated with Jade’s dependence on third-party vendors for the development, manufacture and supply of its product candidates may occur; and the other risks, uncertainties and factors more fully described in Jade’s most recent filings with the Securities and Exchange Commission (including the Quarterly Report on Form 10-Q for the quarter ended June 30, 2026). Should one or more of these risks or uncertainties materialize, or should any of Jade’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. You should not place undue reliance on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Jade does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements, except as required by law. This communication does not purport to summarize all of the conditions, risks and other attributes of an investment in Jade.

Jade Biosciences Contact

Zane Goodwin
IR@JadeBiosciences.com
Media@JadeBiosciences.com

NASHVILLE, Tenn., Sept. 30, 2026 (GLOBE NEWSWIRE) — Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that 15 scientific abstracts featuring data from across its ophthalmic portfolio will be presented at two major eyecare meetings:

• American Academy of Optometry’s (AAOpt) Annual meeting taking place September 30 – October 3, 2026, in Anaheim, California; and
• American Academy of Ophthalmology’s (AAO) Annual Meeting, taking place October 9–12, 2026, in New Orleans, Louisiana.

Harrow will have 13 presentations at AAOpt 2026 and two at AAO 2026, spanning dry eye disease, vernal keratoconjunctivitis (VKC), ocular inflammation, chronic blepharitis, and post-operative inflammation and pain. The research includes Phase 3 trial results, pooled Phase 3 analyses, 52-week long-term safety data, a randomized, double-masked comparative study, real-world evidence, and systematic reviews and meta-analyses. Featured Harrow products include VEVYE®, VERKAZIA®, FLAREX®, and BYQLOVI®.

“Fifteen presentations across the two Academies reflect the breadth of Harrow’s ophthalmic portfolio and the growing body of clinical evidence supporting it,” said Amir Shojaei, PhD, PharmD, Chief Scientific Officer of Harrow. “We are committed to generating and sharing clinically relevant data that can help optometrists and ophthalmologists make informed treatment decisions for their patients.”

Presentation Details

Harrow’s scientific presentations are listed below.

American Academy of Optometry – AAOpt 2026 Anaheim September 30 – October 3, 2026  |  Anaheim Convention Center, Anaheim, CA  |  13 presentations  |  All times Pacific
Date / Time	Presentation Title	Presenter(s)	Product / Area
Thu., Oct. 1 4:30–6:30 p.m. Evening Poster Session	A Clinical Trial to Evaluate Corneal Endothelial Health Over 52 Weeks in Dry Eye Disease Patients Treated with Cyclosporine Ophthalmic Solution, 0.1%	Patrick Vollmer, OD	VEVYE® – Dry Eye Disease
Thu., Oct. 1 4:30–6:30 p.m. Evening Poster Session	Rapid Dryness Improvement with Cyclosporine 0.1% in Perfluorobutylpentane and Perfluorobutylpentane Alone in Dry Eye Disease: Pooled Subgroup Analysis	Milton Hom, OD	VEVYE® – Dry Eye Disease
Thu., Oct. 1 4:30–6:30 p.m. Evening Poster Session	Patient-Reported Blurred Vision Improvement with Cyclosporine 0.1%/PFBP in Dry Eye Disease with Severe Corneal Staining: Phase 3 Pool	Eric Schmidt, OD	VEVYE® – Dry Eye Disease
Thu., Oct. 1 4:30–6:30 p.m. Evening Poster Session	Real-World Improvement in Fluorescein TBUT with VEVYE in Severe Dry Eye Disease with Neuro-Ophthalmic Comorbidity	Faraz Haghighi, OD	VEVYE® – Dry Eye Disease
Thu., Oct. 1 4:30–6:30 p.m. Evening Poster Session	OSDI Responder Rates with Real-World VEVYE in a Severely Symptomatic Neuro-Ophthalmic Dry Eye Cohort	Faraz Haghighi, OD	VEVYE® – Dry Eye Disease
Thu., Oct. 1 4:30–6:30 p.m. Evening Poster Session	Safety of Cyclosporine A 0.1% Cationic Emulsion in Vernal Keratoconjunctivitis: Pooled NOVATIVE/VEKTIS with Prior-Antiallergic Subgroup	Kyle Klute, OD	VERKAZIA® – VKC
Thu., Oct. 1 4:30–6:30 p.m. Evening Poster Session	Course of Individual Symptom Relief with Cyclosporine A 0.1% Cationic Emulsion in Pediatric Severe Vernal Keratoconjunctivitis: VEKTIS Phase III Trial	Ruchita Shah, OD	VERKAZIA® – VKC
Thu., Oct. 1 4:30–6:30 p.m. Evening Poster Session	Steroid Rescue Reduction and Treatment Compliance in Pediatric Vernal Keratoconjunctivitis: Longitudinal Findings from the VEKTIS Phase 3 Trial	Andrew Royer, OD	VERKAZIA® – VKC
Thu., Oct. 1 4:30–6:30 p.m. Evening Poster Session	Topical Calcineurin Inhibitors in Pediatric Vernal Keratoconjunctivitis: A Systematic Review and Meta-Analysis of Cyclosporine A and Tacrolimus	Kaleb Abbott, OD	VERKAZIA® – VKC
Thu., Oct. 1 4:30–6:30 p.m. Evening Poster Session	Randomized, Double-Masked Comparison of Ocular Tolerability and Patient Preference for Fluorometholone Acetate Suspension vs. Loteprednol Etabonate Gel	Josh Davidson, OD	FLAREX® – Ocular Inflammation
Thu., Oct. 1 4:30–6:30 p.m. Evening Poster Session	Treatment Outcomes in Chronic Blepharitis Managed by Topical Prescription Therapies: A Systematic Review and Meta-Analysis	Selina McGee, OD Richard Adler, OD	Blepharitis – Disease State
Fri., Oct. 2 1:00–3:00 p.m. Poster Session	Early Symptom Relief with Cyclosporine A 0.1% Cationic Emulsion in Pediatric Vernal Keratoconjunctivitis: A Descriptive Analysis	Chris Jacquinot, OD Shane Kannarr, OD	VERKAZIA® – VKC
Fri., Oct. 2 1:00–3:00 p.m. Scientific Program / Residents Poster Session	Pediatric Ocular Comfort of Topical Cyclosporine A 0.05% and 0.1% Cationic Emulsion in Vernal Keratoconjunctivitis	Elsa Sheerer, OD	VERKAZIA® – VKC

American Academy of Ophthalmology – AAO 2026 Annual Meeting October 9–12, 2026  |  Ernest N. Morial Convention Center, New Orleans, LA  |  2 presentations  |  All times Central
Date / Time	Presentation Title	Presenter(s)	Product / Area
Sat., Oct. 10 9:15–10:15 a.m. Podium Poster PT03 – Cataract	Clobetasol Propionate for Post-Cataract Inflammation and Pain: Second Phase 3 Trial with Corneal Endothelial Cell Safety	Jason Bachrach, MD	BYQLOVI® – Post-Op Care
Poster on Demand Poster PO277	Clobetasol Propionate Nanosuspension for Post-Cataract Inflammation and Pain: First Pivotal Phase 3 Trial	Steven Silverstein, MD Eva Liang, MD	BYQLOVI® – Post-Op Care

VEVYE® (cyclosporine ophthalmic solution) 0.1%
Indications and Usage
VEVYE® (cyclosporine ophthalmic solution) 0.1% is indicated for the treatment of the signs and symptoms of dry eye disease.

Important Safety Information
WARNINGS AND PRECAUTIONS
Potential for Eye Injury and Contamination: To avoid the potential for eye injury and/or contamination, patients should not touch the bottle tip to the eye or other surfaces.

Use with Contact Lenses: VEVYE® should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following the administration of VEVYE®.

ADVERSE REACTIONS
In clinical trials with 738 subjects receiving at least 1 dose of VEVYE®, the most common adverse reactions were instillation site reactions (8%) and temporary decreases in visual acuity (3%).

Please see full Prescribing Information for VEVYE.

VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1%
Indications and Usage
Verkazia® (cyclosporine ophthalmic emulsion) 0.1% is a calcineurin inhibitor immunosuppressant indicated for the treatment of vernal keratoconjunctivitis in children and adults.

Important Safety Information
WARNINGS AND PRECAUTIONS
Potential for eye injury and contamination: To avoid the potential for eye injury and contamination, advise patient not to touch the vial tip to the eye or other surfaces.

ADVERSE REACTIONS
The most common adverse reactions reported in greater than 5% of patients were eye pain (12%) and eye pruritus (8%), which were usually transitory and occurred during instillation.

Please see full Prescribing Information for VERKAZIA.

FLAREX® (fluorometholone acetate ophthalmic suspension) 0.1%
Indications and Usage
FLAREX® (fluorometholone acetate ophthalmic suspension) 0.1% is indicated for use in the treatment of steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the eye.

Important Safety Information
CONTRAINDICATIONS
Contraindicated in acute superficial herpes simplex keratitis, vaccinia, varicella, and most other viral diseases of the cornea and conjunctiva; mycobacterial infection of the eye; fungal diseases; acute purulent untreated infections, which like other diseases caused by microorganisms, may be masked or enhanced by the presence of the steroid; and in those persons who have known hypersensitivity to any component of this preparation.

WARNINGS AND PRECAUTIONS
Topical Ophthalmic Use: Not for injection.

Intraocular Pressure Increase: Prolonged use may result in glaucoma, damage to the optic nerve, and defects in visual acuity and visual field. It is advisable that the intraocular pressure be checked frequently.

Cataracts: Use of corticosteroids may result in cataract formation.

Delayed Healing: Topical ophthalmic corticosteroids may slow corneal wound healing. In those diseases causing thinning of the cornea or sclera, perforation has been known to occur with chronic use of topical steroids.

Viral Infections: Use in the treatment of herpes simplex infection requires great caution.

Bacterial Infections: Use of corticosteroids may suppress the host response and thus aid in the establishment of secondary ocular infections. Acute purulent infections of the eye may be masked or exacerbated by the presence of steroid medication.

Fungal Infections: Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use.

Contamination: Do not touch dropper tip to any surface as this may contaminate the suspension.

Contact Lens Wear: Contact lenses should be removed during instillation of FLAREX but may be reinserted 15 minutes after instillation.

Temporarily Blurred Vision: Vision may be temporarily blurred following dosing with FLAREX. Care should be exercised in operating machinery or driving a motor vehicle.

ADVERSE REACTIONS
Glaucoma with optic nerve damage, visual acuity and field defects, cataract formation, secondary ocular infection following suppression of host response, and perforation of the globe may occur.

Post marketing Experience: The following reaction has been identified during post marketing use of FLAREX in clinical practice. Because reactions are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The reaction, which has been chosen for inclusion due to either its seriousness, frequency of reporting, possible causal connection to FLAREX, or a combination of these factors, includes dysgeusia. The following rare adverse reactions have been reported: Cushing’s syndrome and adrenal suppression may occur after very frequent use of topical ophthalmic corticosteroids, particularly in very young children.

Please see full Prescribing Information for FLAREX.

BYQLOVI® (clobetasol propionate ophthalmic suspension) 0.05%
Indications and Usage
BYQLOVI® (clobetasol propionate ophthalmic suspension) 0.05% is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery.

Important Safety Information
CONTRAINDICATIONS
BYQLOVI is contraindicated in most active viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures.

WARNINGS AND PRECAUTIONS
Intraocular Pressure (IOP) Increase: Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma. If BYQLOVI is used for 10 days or longer, IOP should be monitored.

Cataracts: Prolonged use of corticosteroids may result in posterior subcapsular cataract formation.

Delayed Healing: The use of corticosteroids after cataract surgery may delay healing and increase the incidence of bleb formation.

Corneal and Scleral Melting: In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical corticosteroids. The initial prescription and renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy, and where appropriate, fluorescein staining.

Bacterial Infections: Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions, steroids may mask infection or enhance existing infection. If signs and symptoms fail to improve after 2 days, the patient should be reevaluated.

Viral Infections: Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular corticosteroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex).

Fungal Infections: Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local corticosteroid application. Fungus invasion must be considered in any persistent corneal ulceration where a corticosteroid has been used or is in use. Fungal culture should be taken when appropriate.

Risk of Contamination: Do not allow the dropper tip to touch any surface, as this may contaminate the ophthalmic suspension.

Contact Lens Wear: BYQLOVI should not be instilled while wearing contact lenses. Remove contact lenses prior to instillation of BYQLOVI. The preservative in BYQLOVI may be absorbed by soft contact lenses. Lenses may be reinserted after 15 minutes following administration of BYQLOVI.

ADVERSE REACTIONS
Ocular adverse reactions occurring in ≥ 1% of subjects in clinical studies who received BYQLOVI included eye inflammation (2%), corneal edema (2%), anterior chamber inflammation (2%), cystoid macular edema (2%), intraocular pressure elevation (1%), photophobia (1%) and vitreous detachment (1%). Many of these reactions may have been the consequence of the surgical procedure.

Please see full Prescribing Information for BYQLOVI.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

About Harrow

Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and diseases of the retina. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com and connect with us on LinkedIn.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, risks related to: liquidity or results of operations; our ability to successfully implement our business plan, develop and commercialize our products, product candidates and proprietary formulations in a timely manner or at all, identify and acquire additional products, manage our pharmacy operations, service our debt, obtain financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of our previous acquisitions and any other acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical companies, outsourcing facilities and pharmacies; general economic and business conditions, including inflation and supply chain challenges; regulatory and legal risks and uncertainties related to our pharmacy operations and the pharmacy and pharmaceutical business in general, including the ongoing communications with the U.S. Food and Drug Administration relating to compliance and quality plans at our outsourcing facility in New Jersey; physician interest in and market acceptance of our current and any future formulations and compounding pharmacies generally. These and additional risks and uncertainties are more fully described in Harrow’s filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2025, and other filings with the SEC. Such documents may be read free of charge on the SEC’s web site at sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Harrow undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Investor & Media Contact:
Mike Biega
Vice President of Investor Relations and Communications
mbiega@harrowinc.com
617-913-8890

New clearance to further simplify bedside EEG interpretation and enable more informed interventions for patients of all ages across multiple indications

SUNNYVALE, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) — CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell” or the “Company”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that the U.S. Food and Drug Administration (FDA) has cleared new software for the Ceribell System that makes it easier and faster for clinicians to interpret longitudinal brain activity and make appropriate clinical decisions.¹

Brain monitoring with electroencephalography (EEG) can generate hours of complex data that can be difficult to interpret in a timely manner. Ceribell’s newly cleared software takes that raw information and turns it into simple, easy-to-read trends at the bedside, so clinicians can spot meaningful changes in brain activity sooner when every minute matters.

The software update will add three capabilities to the Ceribell Platform:

• Alpha-Delta Ratio (ADR) & Relative Alpha (RA) Trending: Delivers continuous brain monitoring which can be used to help catch early signs of brain distress and reduced blood flow in high-risk patients, such as those suffering from aneurysmal subarachnoid hemorrhage (SAH), enabling proactive intervention.
• Burst Suppression (BS) Monitoring: Provides a clear, real-time picture of brain activity that can be used to help clinicians safely fine-tune sedation drugs when treating severe, ongoing seizures or controlling brain swelling.
• Amplitude-Integrated EEG (aEEG): Offers simplified, long-term monitoring of background brain activity, bringing standard-of-care neonatal assessment to the NICU while complementing adult ICU monitoring.

Notably, this clearance carries no age restriction. The same easy-to-use trends are available whether the patient is a premature newborn in the NICU or an adult patient in the emergency department or ICU.

“In critical care, time is brain, and every hour spent waiting for interpretation of EEG is time lost delivering treatment at the bedside,” said Jane Chao, Ph.D., co-founder and CEO of Ceribell. “We expect to integrate these new features through an automatic software update in the first half of 2027.”

The introduction of these algorithms will build on Ceribell’s continued expansion of its AI-powered EEG platform across the acute-care setting, including recent clearances for neonatal seizure detection² and delirium monitoring.³ Together, these updates reflect Ceribell’s ongoing commitment to making comprehensive brain monitoring available to a wider variety of patients — regardless of age or care setting.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including statements regarding the benefits of Ceribell’s technology and the continued evolution of the Ceribell platform, are forward-looking statements. These statements are based on management’s current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those described, including those related to regulatory approvals, clinical use and adoption, market acceptance, and competition, as described under the “Risk Factors” sections of the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other reports filed with the U.S. Securities and Exchange Commission (“SEC”). These filings are available on the SEC’s website and on Ceribell’s investor relations website. Ceribell undertakes no obligation to update any forward-looking statements as a result of new information, future events, or otherwise, except as required by law.

About Ceribell, Inc.
Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute-care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow the company on LinkedIn.

Investor Contact
Brian Johnston
Gilmartin Group
Investors@ceribell.com

Media Contact
Laura Hartlieb
Press@ceribell.com

¹ FDA 510(k) Clearance Letter K261712
² FDA 510(k) Clearance Letter K252070
³ FDA 510(k) Clearance Letter K251936

New clearance to further simplify bedside EEG interpretation and enable more informed interventions for patients of all ages across multiple indications

SUNNYVALE, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) — CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell” or the “Company”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that the U.S. Food and Drug Administration (FDA) has cleared new software for the Ceribell System that makes it easier and faster for clinicians to interpret longitudinal brain activity and make appropriate clinical decisions.¹

Brain monitoring with electroencephalography (EEG) can generate hours of complex data that can be difficult to interpret in a timely manner. Ceribell’s newly cleared software takes that raw information and turns it into simple, easy-to-read trends at the bedside, so clinicians can spot meaningful changes in brain activity sooner when every minute matters.

The software update will add three capabilities to the Ceribell Platform:

• Alpha-Delta Ratio (ADR) & Relative Alpha (RA) Trending: Delivers continuous brain monitoring which can be used to help catch early signs of brain distress and reduced blood flow in high-risk patients, such as those suffering from aneurysmal subarachnoid hemorrhage (SAH), enabling proactive intervention.
• Burst Suppression (BS) Monitoring: Provides a clear, real-time picture of brain activity that can be used to help clinicians safely fine-tune sedation drugs when treating severe, ongoing seizures or controlling brain swelling.
• Amplitude-Integrated EEG (aEEG): Offers simplified, long-term monitoring of background brain activity, bringing standard-of-care neonatal assessment to the NICU while complementing adult ICU monitoring.

Notably, this clearance carries no age restriction. The same easy-to-use trends are available whether the patient is a premature newborn in the NICU or an adult patient in the emergency department or ICU.

“In critical care, time is brain, and every hour spent waiting for interpretation of EEG is time lost delivering treatment at the bedside,” said Jane Chao, Ph.D., co-founder and CEO of Ceribell. “We expect to integrate these new features through an automatic software update in the first half of 2027.”

The introduction of these algorithms will build on Ceribell’s continued expansion of its AI-powered EEG platform across the acute-care setting, including recent clearances for neonatal seizure detection² and delirium monitoring.³ Together, these updates reflect Ceribell’s ongoing commitment to making comprehensive brain monitoring available to a wider variety of patients — regardless of age or care setting.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including statements regarding the benefits of Ceribell’s technology and the continued evolution of the Ceribell platform, are forward-looking statements. These statements are based on management’s current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those described, including those related to regulatory approvals, clinical use and adoption, market acceptance, and competition, as described under the “Risk Factors” sections of the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other reports filed with the U.S. Securities and Exchange Commission (“SEC”). These filings are available on the SEC’s website and on Ceribell’s investor relations website. Ceribell undertakes no obligation to update any forward-looking statements as a result of new information, future events, or otherwise, except as required by law.

About Ceribell, Inc.
Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute-care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow the company on LinkedIn.

Investor Contact
Brian Johnston
Gilmartin Group
Investors@ceribell.com

Media Contact
Laura Hartlieb
Press@ceribell.com

¹ FDA 510(k) Clearance Letter K261712
² FDA 510(k) Clearance Letter K252070
³ FDA 510(k) Clearance Letter K251936

The acquired business generated approximately $6.6 million of adjusted EBITDA in fiscal year 2025; Bloom, Advertise Purple’s proprietary data and analytics platform with more than 111 million performance records, joins ONAR Labs alongside Retina AI and Cortex

Miami, FL, Sept. 30, 2026 (GLOBE NEWSWIRE) — ONAR Holding Corporation (OTC PINK: ONAR) (“ONAR” or the “Company”), an AI-powered marketing platform, today announced that it has completed its acquisition of Advertise Purple, a Santa Monica, California-based affiliate marketing agency, in the largest acquisition in the Company’s history, funded by the $15 million financing announced yesterday. On a pro forma basis, the combined company generated approximately $23.5 million of revenue in fiscal year 2025, approximately seven times ONAR’s reported standalone revenue for the same period. Advertise Purple contributes a business that generated approximately $17.1 million of net revenue and $4.4 million of net income in fiscal year 2025, representing approximately $6.6 million of adjusted EBITDA, a non-GAAP measure reconciled below. Total consideration for the acquisition is up to $27,825,000, assuming all earnout thresholds are met, and the complete terms are set forth in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 30, 2026.

Advertise Purple is a leading U.S. affiliate and partnership marketing agency, managing affiliate programs for more than 400 active brands with no single client representing more than approximately five percent of revenue. Advertise Purple Chief Executive Officer Jonathan Moisan and Chief Growth Officer Rowland Hazard will continue to lead the business, and the consideration is structured so that a meaningful portion is earned through the future growth of the business they run.

The Bloom Platform

At the core of Advertise Purple’s operating model is Bloom, its proprietary data, analytics, and workflow platform. Bloom serves as both the client-facing performance dashboard and the internal operating system through which Advertise Purple manages affiliate programs at scale: it ingests first-party client data across transactions, products, and affiliate activity, and drives partner selection, commission optimization, and program management across the agency’s book. The platform holds more than 111 million performance records accumulated across thousands of client programs, and in the past year Advertise Purple added AI-enabled natural language access to the platform.

Bloom now joins ONAR Labs, the Company’s technology division, alongside Retina AI, ONAR’s predictive customer intelligence platform, and Cortex, its offline and online sales attribution platform. The combination is the reason the Company believes this acquisition is transformational rather than merely additive: affiliate marketing is one of the fastest-growing channels in performance marketing and remains one of the hardest to measure, and the combination of Bloom’s accumulated performance data with Retina AI’s predictive modeling and Cortex’s attribution gives ONAR the components of a measurement capability the affiliate category has lacked. As the Company wrote in its July letter to stockholders, “We buy strong agencies, we put our own technology inside them, and the same team serves more clients.”

The acquisition also transforms the profile of the Company as it pursues the uplisting to the Nasdaq Stock Market announced in its July letter to stockholders. That letter set out four priorities: completing a transformative acquisition, closing a proposed $15 million financing, converting a portion of outstanding debt into equity, and pursuing the Nasdaq listing. With the financing announced yesterday and the acquisition completed today, three of the four are done. The scale, profitability, and technology the combined company now carries are foundational to the fourth, and the pursuit of the listing continues as described in the Company’s filings.

“Fourteen months ago, this company was behind on its filings and carrying a balance sheet that limited every decision we made. Today, Advertise Purple, its team, and the Bloom platform are part of ONAR, and the plan we published in July is three-quarters complete,” said Claude Zdanow, Chief Executive Officer of ONAR. “I want stockholders to understand why this one is different. We didn’t just buy revenue. We bought the largest data asset this company has ever owned, in a channel that’s growing fast and has never been measured well, and we build the technology that fixes exactly that. What comes now is the part I respect most: integration, execution, and earning the numbers. We closed on a date we set ourselves, and we intend to keep working that way.”

“We spent a decade building Advertise Purple into the agency brands trust with their affiliate spend, and Bloom is a big part of why they trust us,” said Jonathan Moisan, Chief Executive Officer of Advertise Purple. “Joining ONAR puts real engineering behind Bloom, and pairing it with Retina AI and Cortex means our clients get answers this channel has never been able to give them. Our team stays, our standards stay, and now we have a platform behind us.”

Advertise Purple was advised by Woodland Park Capital Advisors, with support from PanArgent Capital Advisors.

About Advertise Purple

Advertise Purple is a leading U.S. affiliate and partnership marketing agency based in Santa Monica, California. The agency designs, manages, and optimizes affiliate programs for more than 400 active brands across e-commerce, consumer products, software, and services, powered by Bloom, its proprietary data, analytics, and workflow platform.

About ONAR Holding Corporation

ONAR Holding Corporation (OTC PINK: ONAR) is an AI-powered marketing platform. ONAR owns and operates a group of specialist marketing agencies serving middle-market and growth-stage brands across performance marketing, creative, and commerce. Its technology division, ONAR Labs, develops and houses the Company’s proprietary technology, including ONAR AI, a marketing intelligence platform deployed across the Company’s agencies to improve productivity; Retina AI, a predictive customer intelligence platform; and Cortex, an offline and online sales attribution platform. ONAR continues to expand the platform through disciplined acquisitions, including JUICE, Scale Partner, and Advertise Purple. Learn more at www.onar.com.

Non-GAAP Financial Measures and Unaudited Pro Forma Information

Adjusted EBITDA is a non-GAAP financial measure and should not be considered an alternative to net income or any other measure prepared in accordance with GAAP. Advertise Purple’s adjusted EBITDA for fiscal year 2025 of approximately $6.6 million is derived from its net income of approximately $4.4 million, adjusted for the following items identified in an independent quality of earnings review: compensation-related adjustments of approximately $712,000; state franchise taxes of approximately $520,000; website and software development costs of approximately $435,000; officer compensation of approximately $144,000; excess rent of approximately $116,000; and professional fees, travel and entertainment, and other items of approximately $224,000. Advertise Purple’s historical financial information is unaudited. The pro forma combined revenue figure in this release is preliminary, unaudited, presented for illustrative purposes only, and gives effect to the acquisitions completed by the Company during and after fiscal year 2025 as if they had occurred at the beginning of that period, and is not necessarily indicative of the results that would have been achieved had the transactions occurred on the dates indicated. The Company expects to file the historical financial statements of Advertise Purple and unaudited pro forma financial information required by Items 2.01 and 9.01 of Form 8-K within the time period permitted by those Items.

No Offer or Solicitation

This press release is for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy any securities. Securities issued in the financing referenced above were offered and sold in a private placement to accredited investors, have not been registered under the Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Forward-Looking Statements

This press release contains statements that the Company believes to be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including statements regarding the Company’s future financial condition, results of operations, business operations and business prospects, the integration of Advertise Purple, the payment of earnout and seller note obligations, pro forma financial information, any potential conversion of securities, any potential uplisting, and any other potential acquisitions, financings, and debt restructurings, are forward-looking statements. Pro forma combined figures are presented for illustrative purposes only and are not necessarily indicative of the results that would have been achieved had the acquisition occurred in the period presented, and do not constitute guidance. Words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “predict,” “believe,” and similar words and expressions are intended to identify forward-looking statements. These statements reflect the Company’s current expectations, are not guarantees of future performance, and involve known and unknown risks and uncertainties, including the substantial doubt about the Company’s ability to continue as a going concern described in its SEC filings, the Company’s working capital deficit and increased indebtedness following the transactions described above, integration risks, the risk that expected benefits of the acquisition are not realized, the need for additional financing, market conditions, competition, client retention, and regulatory changes, any of which could cause actual results to differ materially. Detailed risk factors are included in the Company’s filings with the SEC, including its Annual Report on Form 10-K and its Quarterly Report on Form 10-Q. These forward-looking statements speak only as of the date hereof. The Company assumes no obligation to update these statements except as required by law.

Media and Investor Contact
ONAR Holding Corporation
Investor Relations
IR@onar.com
(213) 437-3081
www.onar.com